Möchten Sie immer auf dem neuesten Stand bleiben?

MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported...

Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN...

First clinic launched April 14, 2026, supporting first-year Physician Assistant observership requirements at the University of TorontoStudents will observe clinicians delivering care through Rocket...

Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based...

Austin, TX, USA, May 12, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Clinical Informatics Market Size, Trends and Insights By Type (Electronic Health...

Gala GLP-1 scam or legit? Compounded GLP-1/GIP from $179/mo. Licensed provider review. No insurance. No prescription guarantee. All 50 states.

Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc....

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase...

First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2%U.S. revenue of $49.3 million, representing...

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand...